ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Numerous in vitro experiments have confirmed that metformin, an AMPK agonist, can inhibit the growth of the AML cell lines OCI/AML2, OCI/AML3, and THP-1 in vitro; is a potential drug for adjuvant therapy for leukemia; and inhibits the growth and survival of chronic myeloid leukemia (CML) cells expressing BCR-ABL mutations in vitro [69, 70].